52North
Founded 2018 · 27 employees on LinkedIn · 5 known investors
52 North Health develops the patented Aster platform, a portable finger-prick blood test and companion app that measures cell-based and soluble biomarkers to identify immunosuppressed patients at risk of neutropenic sepsis. It also builds digital tools for remote triaging and management of emergency cancer care, working with patients and clinicians to make emergency care safer.
Also known as 52 North Health · 52North
Investors · 5
Company profile
researched Aug 202652North develops in-vitro diagnostic and digital solutions intended to make emergency care safer and more effective, working with patients and clinicians. Its core technology is the patented Aster™ platform, described by the company as the first portable platform for cell measurement, which enables multiplexing across cell-based and soluble biomarkers from a single sample in a rapid, easy-to-use and portable format.
Products built on and around this platform include Neutrocheck®, a portable finger-prick blood test and companion app designed to identify immunosuppressed patients at risk of neutropenic sepsis, and ACORN™, a digital tool for patients and healthcare professionals supporting remote triaging and management of emergency cancer care needs. In 2025 the company added ARC™, a product directed at nuclear emergency preparedness.
Latest developments
In December 2024 the company reported being selected from more than 2,000 applicants for the NATO DIANA programme. In March 2025 it appointed John Jeans CBE as Chair, and in September 2025 it launched ARC™ for nuclear emergency preparedness with NATO backing.
▸Full profile — market position, technology, go-to-market
Market position
52North positions itself around emergency care diagnostics and digital triage, describing Aster™ as the world's first portable platform for cell measurement.
Technology
The company's patented Aster™ platform is a portable system for cell measurement that allows multiplexing across cell-based and soluble biomarkers from a single sample, positioned for rapid, easy-to-use point-of-care formats. It is applied in Neutrocheck®, a finger-prick blood test paired with an app, while ACORN™ provides a digital triage and management layer for emergency cancer care.
Go-to-market
Patients and healthcare professionals involved in emergency care, including immunosuppressed cancer patients at risk of neutropenic sepsis and clinicians managing emergency cancer care needs; the ARC™ product targets nuclear emergency preparedness use cases.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filings52North announced the launch of ARC™, aimed at nuclear emergency preparedness, with NATO backing.
52North was selected from over 2,000 applicants for the NATO DIANA programme.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- 52north Seed52north.health · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 52North do?
- 52North builds in-vitro diagnostic and digital products, including the portable Aster cell-measurement platform, for emergency care.
- Who are 52North's investors?
- 52North's investors include Cambridge Angels group, Future Planet Capital, Meridian Health Ventures, Parkwalk Advisors, Milltrust International Group.